Intranasal Diclofenac Sodium — Competitive Intelligence Brief

Intranasal Diclofenac Sodium (Intranasal Diclofenac Sodium) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Nonsteroidal anti-inflammatory drug (NSAID). Area: Pain Management.

phase 3 Nonsteroidal anti-inflammatory drug (NSAID) COX-1 and COX-2 Pain Management Small molecule

Target snapshot

Intranasal Diclofenac Sodium (Intranasal Diclofenac Sodium) — Bezmialem Vakif University. Intranasal diclofenac sodium is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX) enzymes to reduce prostaglandin synthesis, thereby decreasing inflammation and pain.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Intranasal Diclofenac Sodium TARGET	Intranasal Diclofenac Sodium	Bezmialem Vakif University	phase 3	Nonsteroidal anti-inflammatory drug (NSAID)	COX-1 and COX-2
Cytotec	Misoprostol	Pfizer	marketed	NSAID combined with prostaglandin analog	Cyclooxygenase (COX-1 and COX-2); Prostaglandin receptors	1988-01-01
Ketorolac Ophthalmic Solution	Ketorolac Ophthalmic Solution	Bausch & Lomb Incorporated	marketed	Nonsteroidal anti-inflammatory drug (NSAID)	Cyclooxygenase (COX-1 and COX-2)
ABS	ABS	Teva Branded Pharmaceutical Products R&D, Inc.	marketed	Nonsteroidal anti-inflammatory drug (NSAID)	COX-1 and COX-2
Ibuprofen Acid	Ibuprofen Acid	Reckitt Benckiser Healthcare (UK) Limited	marketed	Nonsteroidal anti-inflammatory drug (NSAID)	COX-1 and COX-2
INF1.0 + IBU	INF1.0 + IBU	St. Justine's Hospital	marketed	Interferon alfa + NSAID combination	Interferon alfa receptor (IFNAR); COX-1 and COX-2
Metamizole and Ibuprofen	Metamizole and Ibuprofen	University Hospital, Basel, Switzerland	marketed	Nonsteroidal anti-inflammatory drug (NSAID) combination	Cyclooxygenase (COX-1 and COX-2)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Nonsteroidal anti-inflammatory drug (NSAID) class)

1. Università degli Studi di Brescia · 4 drugs in this class
2. Bausch & Lomb Incorporated · 4 drugs in this class
3. Bayer · 3 drugs in this class
4. Pfizer · 3 drugs in this class
5. Azienda USL Reggio Emilia - IRCCS · 3 drugs in this class
6. Organon and Co · 3 drugs in this class
7. Johnson & Johnson Consumer Inc., McNeil Consumer Healthcare Division · 2 drugs in this class
8. Bezmialem Vakif University · 2 drugs in this class
9. Guang'anmen Hospital of China Academy of Chinese Medical Sciences · 2 drugs in this class
10. Center For Excellence In Eye Care · 2 drugs in this class